TRANSFORMING RISKS INTO RETURNS: XCELLERATE® MONITORING CASE STUDY A large multi-national drug company engaged Covance to conduct the monitoring for sites in the US and Canada for a large Phase III endpoint study. Roughly 27,000 patients were enrolled in the study, of which about 8,000 were in the US and Canada. Understanding the Challenge ? Optimizing shared site management and monitoring responsibilities with multiple vendors ? M ain

Join for free to read